Evidence map›Paper›PMID 38915327›Full record

ArticleRSC advances2024

Disrupting redox homeostasis for tumor therapy based on PDT/chemo/ferroptosis therapeutic hybrid liposomes.

Yuanping Huang, Hongsen Liu, Yanfei Zhao, Haoran Chen, Qiqing Li, Xiaodan Li, Shucheng Hua, Dianbo Cao, Yulei Chang

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanping HuangDepartment of Respiratory Medicine, The First Hospital of Jilin University Changchun 130021 China ddjy@jlu.edu.cn hsc@jlu.edu.cn.ORCID https://orcid.org/0000-0002-0776-5458
Hongsen LiuKey Laboratory of Luminescence Science and Technology, Chinese Academy of Sciences & State Key Laboratory of Luminescence and Applications, Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences Changchun 130033 Jilin China.
Yanfei ZhaoDepartment of Respiratory Medicine, The First Hospital of Jilin University Changchun 130021 China ddjy@jlu.edu.cn hsc@jlu.edu.cn.
Haoran ChenKey Laboratory of Luminescence Science and Technology, Chinese Academy of Sciences & State Key Laboratory of Luminescence and Applications, Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences Changchun 130033 Jilin China.
Qiqing LiKey Laboratory of Luminescence Science and Technology, Chinese Academy of Sciences & State Key Laboratory of Luminescence and Applications, Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences Changchun 130033 Jilin China.
Xiaodan LiDepartment of Respiratory Medicine, The First Hospital of Jilin University Changchun 130021 China ddjy@jlu.edu.cn hsc@jlu.edu.cn.
Shucheng HuaDepartment of Respiratory Medicine, The First Hospital of Jilin University Changchun 130021 China ddjy@jlu.edu.cn hsc@jlu.edu.cn.
Dianbo CaoDepartment of Radiology, The First Hospital of Jilin University Changchun 130021 China caodb@jlu.edu.cn.
Yulei ChangKey Laboratory of Luminescence Science and Technology, Chinese Academy of Sciences & State Key Laboratory of Luminescence and Applications, Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences Changchun 130033 Jilin China.ORCID https://orcid.org/0000-0001-7223-1797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synergistic photodynamic therapy (PDT) with other therapeutic modalities can enhance the therapeutic efficacy of tumor treatment and reduce the adverse effects associated with drug leakage and off-target accumulation. However, shaping combined strategies for synergistic therapy remains challenging. Herein, we developed versatile hybrid liposomes self-assembled from Ce6-lipid conjugates and loaded with the chemo drug doxorubicin (DOX) and ferroptosis inducer Fe

Identifiers

PMID38915327
PMCPMC11195642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.